HK1218119A1 - 蛋白激酶抑制劑 - Google Patents

蛋白激酶抑制劑

Info

Publication number
HK1218119A1
HK1218119A1 HK16106182.7A HK16106182A HK1218119A1 HK 1218119 A1 HK1218119 A1 HK 1218119A1 HK 16106182 A HK16106182 A HK 16106182A HK 1218119 A1 HK1218119 A1 HK 1218119A1
Authority
HK
Hong Kong
Prior art keywords
protein kinase
kinase inhibitors
certain protein
certain
inhibitors
Prior art date
Application number
HK16106182.7A
Other languages
English (en)
Inventor
Weibo Wang
Xingdong Zhao
Quan Yuan
Hailong Shi
Qiang Tian
Qihong Liu
Zuwen Zhou
Xianlong Wang
Zhifang Chen
Ling Chen
Haohan Tan
Bo Fang
Lihua Jiang
Yanxin Liu
Jing Sun
Fanxin Zeng
Tongshuang Li
Original Assignee
Shanghai Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fochon Pharmaceutical Co Ltd filed Critical Shanghai Fochon Pharmaceutical Co Ltd
Publication of HK1218119A1 publication Critical patent/HK1218119A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16106182.7A 2013-04-18 2016-05-31 蛋白激酶抑制劑 HK1218119A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361813190P 2013-04-18 2013-04-18
PCT/CN2014/075664 WO2014169843A1 (en) 2013-04-18 2014-04-18 Certain protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1218119A1 true HK1218119A1 (zh) 2017-02-03

Family

ID=51730814

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106182.7A HK1218119A1 (zh) 2013-04-18 2016-05-31 蛋白激酶抑制劑

Country Status (7)

Country Link
US (2) US9556171B2 (zh)
EP (1) EP2986611B1 (zh)
CN (2) CN105121443B (zh)
DK (1) DK2986611T3 (zh)
ES (1) ES2724578T3 (zh)
HK (1) HK1218119A1 (zh)
WO (1) WO2014169843A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2986611T3 (da) 2013-04-18 2019-05-06 Shanghai Fochon Pharmaceutical Co Ltd Bestemte proteinkinaseinhibitorer
CN105705494B (zh) 2013-07-18 2017-12-15 锦州奥鸿药业有限责任公司 喹唑啉衍生物及其药物组合物，以及作为药物的用途
PL3290407T3 (pl) * 2013-10-18 2020-09-07 Celgene Quanticel Research, Inc Inhibitory bromodomen
US10730858B2 (en) 2016-07-07 2020-08-04 Bristol-Myers Squibb Company Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
TW201821408A (zh) * 2016-12-01 2018-06-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物的製備方法及其中間體
TWI801394B (zh) * 2017-06-23 2023-05-11 大陸商基石藥業（蘇州）有限公司 作為mek抑制劑的類香豆素環類化合物及其應用
CN117015531A (zh) 2020-12-02 2023-11-07 医肯纳肿瘤学公司 Tead抑制剂及其用途
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022159986A1 (en) 2021-01-25 2022-07-28 Ikena Oncology, Inc. Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
JP2024514879A (ja) * 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド Ｍｅｋ阻害剤及びその使用
WO2023010354A1 (zh) * 2021-08-04 2023-02-09 四川大学华西医院 一种具有egfr抑制活性的小分子化合物及其制备方法与应用
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223142A (en) * 1976-06-16 1980-09-16 E. R. Squibb & Sons, Inc. Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters
CN1045962C (zh) * 1993-01-01 1999-10-27 森德克斯(美国)股份有限公司 吡啶并哒嗪酮或吡啶并哒嗪硫酮化合物,制备它的中间体,含它的药物组合物及其用途
US7598383B2 (en) * 2003-11-19 2009-10-06 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN101541801A (zh) * 2006-08-04 2009-09-23 武田药品工业株式会社 稠杂环衍生物及其用途
US8372863B2 (en) * 2008-02-25 2013-02-12 Merck Sharp & Dohme Corp. Tetrahydro-1H-pyrrolo fused pyridones
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
KR20120099217A (ko) * 2009-09-28 2012-09-07 글락소스미스클라인 엘엘씨 조합물
DK2986611T3 (da) 2013-04-18 2019-05-06 Shanghai Fochon Pharmaceutical Co Ltd Bestemte proteinkinaseinhibitorer

Also Published As

Publication number Publication date
DK2986611T3 (da) 2019-05-06
CN106905316A (zh) 2017-06-30
US20160083376A1 (en) 2016-03-24
WO2014169843A1 (en) 2014-10-23
EP2986611A4 (en) 2016-09-14
ES2724578T3 (es) 2019-09-12
CN105121443B (zh) 2017-04-12
US9556171B2 (en) 2017-01-31
US10022374B2 (en) 2018-07-17
EP2986611B1 (en) 2019-02-06
EP2986611A1 (en) 2016-02-24
CN105121443A (zh) 2015-12-02
US20170105994A1 (en) 2017-04-20
CN106905316B (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
HK1217198A1 (zh) 蛋白激酶抑制劑
IL256946B (en) Bromodomain inhibitors
HK1224297A1 (zh) 布羅莫結構域抑制劑
HK1220459A1 (zh) 激酶抑制劑
HK1215577A1 (zh) 蛋白激酶抑制劑
IL241123A0 (en) Dihydro-pyrrolopyridinones as inhibitors of bromo sites
HK1214813A1 (zh) 激酶抑制劑
HK1218119A1 (zh) 蛋白激酶抑制劑
HK1211578A1 (zh) 作為 激酶抑制劑的酰氨基咪唑並噠嗪
HK1210774A1 (zh) 取代的 -氨基吡啶類蛋白激酶抑制劑
HK1219104A1 (zh) 激酶抑制劑
HK1205506A1 (zh) 炔類化合物的蛋白激酶抑制劑
HK1209726A1 (zh) 蛋白激酶抑制劑
EP3007689A4 (en) NON-SELECTIVE KINASE INHIBITORS
HK1208460A1 (zh) 蛋白激酶抑制劑
EP3071572A4 (en) Protein kinase inhibitors
EP3074401A4 (en) Protein kinase inhibitors
EP3071573A4 (en) Protein kinase inhibitors
GB201307155D0 (en) Kinase inhibitors